dc.contributor.author | Wang, Xiaoli et al. | |
dc.date.accessioned | 2020-06-30T14:56:45Z | |
dc.date.available | 2020-06-30T14:56:45Z | |
dc.date.issued | 2020-04-23 | |
dc.identifier.uri | https://doi.org/10.1101/2020.04.15.20065623 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1860 | |
dc.description.abstract | Background. COVID-19 is a pandemic with no specific antiviral treatments or vaccines. The urgent needs for exploring the neutralizing antibodies from patients with different clinical characteristics are emerging. Methods. A total of 117 blood samples were collected from 70 COVID-19 inpatients and convalescent patients. The presence of neutralizing antibody was determined with a modified cytopathogenic assay based on live SARS-CoV-2. The dynamics of neutralizing antibody levels at different with different clinical characteristics were analyzed. Results. The seropositivity rate reached up to 100.0% within 20 days since onset, and remained 100.0% till day 41-53. The total GMT was 1:163.7 (95% CI, 128.5 to 208.6), and the antibody level was highest during day 31-40 since onset, and then decreased slightly. Individual differences in changes of antibody levels were observed among 8 representative convalescent patients. In multivariate GEE analysis, patients at age of 31-60 and 61-84 had a higher antibody level than those at age of 16-30 (β=1.0518, P=0.0152; β=1.3718, P=0.0020). Patients with a worse clinical classification had a higher antibody titer (β=0.4639, P=0.0227). Conclusions. The neutralizing antibodies were detected even at the early stage of disease, and a significant response showed in convalescent patients. Moreover, changes on antibody levels ware individual specific. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Pandemics | en_US |
dc.subject | Vaccines | en_US |
dc.subject | Antibodies, Viral | en_US |
dc.subject | Betacoronavirus | en_US |
dc.subject | Antibodies, Neutralizing | en_US |
dc.title | Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients | en_US |
eihealth.country | Global (WHO/OMS) | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Protect Health Care Workers / Proteger la Salud de los Trabajadores | en_US |
dc.relation.ispartofjournal | medRxiv | en_US |